Since HBe seroconversion has been associated with the onset of HCC, the inclusion of HBe antigen, anti-HBe antibody, and HBV DNA levels in future studies will allow better correlation between the timing for tumor development and host immune response (24). This evidence concerns the gene HBE1 and hepatocellular carcinoma.